‘Sitagliptin,’ DPP- inhibitors acquire exclusive sale rights
Some of drugs having ‘sitagliptin,’ an antidiabetic substance, acquired the exclusive sale right.
On the 22nd, the Ministry of Food and Drug Safety granted 3 products of ‘sitagliptin phosphate hydrate+metformin hydrochloride,’ a product of ‘sitagliptin phosphate hydrate’ and a product of ‘sitagl...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
